Detection of minimal residual disease in acute lymphoblastic leukemia
- Wendy Stock, MD
Wendy Stock, MD
- Professor of Medicine
- Pritzker School of Medicine of the University of Chicago
- Zeev Estrov, MD
Zeev Estrov, MD
- Professor of Medicine
- University of Texas MD Anderson Cancer Center
More than 80 percent of adults with acute lymphoblastic leukemia (ALL) achieve complete remission (CR) and up to one-half of these patients may experience prolonged disease-free survival and be "cured" of their disease. However, many will experience a recurrence and die of leukemia. Relapse is thought to result from residual leukemic cells that remain following the achievement of "complete" remission, but are below the limits of detection using conventional morphologic assessment. These subclinical levels of residual leukemia are termed "minimal residual disease" (MRD) or "measureable residual disease" and can be evaluated using more sensitive assays. The latter term emphasizes the limitations of available techniques for detecting fewer than one ALL blast in 10,000 normal cells.
MRD assays are routinely used in the clinical care of children with ALL and increasingly in adults as well. MRD measurements during and after induction therapy are highly prognostic and correlate with relapse rates.
This topic review will focus on the methods for MRD monitoring in ALL. The clinical significance of MRD detection in ALL and the use of MRD testing in acute myeloid leukemia and chronic myeloid leukemia are covered separately. (See "Clinical use of minimal residual disease detection in acute lymphoblastic leukemia" and "Remission criteria in acute myeloid leukemia and monitoring for residual disease" and "Overview of the treatment of chronic myeloid leukemia", section on 'Monitoring response'.)
DIFFICULTIES IN DEFINING COMPLETE REMISSION
The primary goal of induction therapy for ALL is achievement of an initial complete remission (CR), defined as the eradication of visible leukemia cells (at least to <5 percent blasts) from the bone marrow and blood detectable by microscopic review and the restoration of normal hematopoiesis (typically with >25 percent cellularity and normal peripheral blood counts).
While CR has historically been defined based upon morphologic criteria, an assessment of MRD can define a more stringent response that is better able to predict prognosis. This approach is supported by several observations that illustrate the difficulty in ascertaining whether a patient with ALL in morphologic CR is likely to remain disease-free:
- McKenna RW, Washington LT, Aquino DB, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001; 98:2498.
- Zeidan MA, Kamal HM, El Shabrawy DA, et al. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children. Blood Cells Mol Dis 2016; 59:113.
- Cavé H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339:591.
- Van Bekkum DW. Reflection on the detection and treatment of leukemia. In: Minimal Residual Disease in Acute Leukemia, Lowenberg B, Hagenbeck A (Eds), Martinus Nijoff, Boston 1984. p.385.
- van Dongen JJ, van der Velden VH, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 2015; 125:3996.
- van der Velden VH, Hoogeveen PG, Pieters R, van Dongen JJ. Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia. Br J Haematol 2006; 133:382.
- Coustan-Smith E, Sancho J, Hancock ML, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002; 100:2399.
- Brisco MJ, Sykes PJ, Hughes E, et al. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol 1997; 99:314.
- van der Velden VH, Jacobs DC, Wijkhuijs AJ, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002; 16:1432.
- Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121:823.
- Bacher U, Zander AR, Haferlach T, et al. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008; 42:145.
- Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012; 120:5173.
- van Dongen JJ, Szczepański T, de Bruijn MA, et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther 1996; 2:121.
- Thörn I, Forestier E, Botling J, et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol 2011; 152:743.
- Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107:1116.
- Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol 1993; 83:412.
- van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13:1901.
- Brüggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24:521.
- Faderl S, Estrov Z. Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance. Cytokines Cell Mol Ther 1998; 4:73.
- Chen IM, Chakerian A, Devidas M, et al. Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method. Br J Haematol 2006; 135:358.
- Ford AM, Fasching K, Panzer-Grümayer ER, et al. Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood 2001; 98:558.
- Konrad M, Metzler M, Panzer S, et al. Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. Blood 2003; 101:3635.
- Beishuizen A, Hählen K, Hagemeijer A, et al. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia 1991; 5:657.
- Steenbergen EJ, Verhagen OJ, van den Berg H, et al. Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B precursor acute lymphoblastic leukemia. Leukemia 1997; 11:1258.
- van Dongen JJ, Breit TM, Adriaansen HJ, et al. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992; 6 Suppl 1:47.
- van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352:1731.
- Cazzaniga G, Lanciotti M, Rossi V, et al. Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. Br J Haematol 2002; 119:445.
- Lee S, Kim DW, Cho B, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003; 120:145.
- Codrington R, O'Connor HE, Jalali GR, et al. Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value. Br J Haematol 2000; 111:1071.
- de Haas V, Oosten L, Dee R, et al. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia. Br J Haematol 2000; 111:1080.
- Drunat S, Olivi M, Brunie G, et al. Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol 2001; 114:281.
- Madzo J, Zuna J, Muzíková K, et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer 2003; 97:105.
- Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990; 76:163.
- Terstappen LW, Loken MR. Five-dimensional flow cytometry as a new approach for blood and bone marrow differentials. Cytometry 1988; 9:548.
- Wells DA, Sale GE, Shulman HM, et al. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol 1998; 110:84.
- Dworzak MN, Fröschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99:1952.
- Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 2009; 131:16.
- van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26:1908.
- Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26:1986.
- Drach J, Drach D, Glassl H, et al. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 1992; 13:893.
- Hurwitz CA, Gore SD, Stone KD, Civin CI. Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells. Leukemia 1992; 6:233.
- Weir EG, Cowan K, LeBeau P, Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999; 13:558.
- Krampera M, Vitale A, Vincenzi C, et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol 2003; 120:74.
- Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351:550.
- Ravandi F, Jorgensen JL, O'Brien SM, et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 2016; 172:392.
- Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96:2691.
- Janossy G, Bollum FJ, Bradstock KF, Ashley J. Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. Blood 1980; 56:430.
- Li A, Zhou J, Zuckerman D, et al. Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood 2003; 102:4520.
- DIFFICULTIES IN DEFINING COMPLETE REMISSION
- SOURCE OF CELLS
- METHODS FOR DETECTING MRD
- POLYMERASE CHAIN REACTION (PCR)
- Real-time quantitative PCR
- - Targets of RQ-PCR
- Ig and TCR gene rearrangements
- Chromosomal rearrangements
- - Advantages of RQ-PCR
- - Limitations of RQ-PCR
- Reverse transcriptase PCR
- - Advantages of RT-PCR
- - Limitations of RT-PCR
- Multiplex PCR with deep sequencing
- MULTICOLOR FLOW CYTOMETRY
- Advantages of flow
- Limitations of flow
- RESPONSE DEFINED
- INFORMATION FOR PATIENTS